Ontario – Toronto GTA – Mississauga
Corporation
www.ymbiosciences.com
Ontario
Toronto GTA
Mississauga
Corporation
active
YM BioSciences Inc. is a life sciences product development. Together with the products from the Australian company, Cytopia Limited, which recently merged into YM, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody™; CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab€™s anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM€™s majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products being developed by Cytopia, the JAK 1/2 inhibitor CYT387 and the novel VDA molecule CYT997 were discovered internally at Cytopia based on research led by Dr. Andrew Wilks who discovered the JAK 1/2 enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.
Country of Ownership: Canada
Year Established: 1994
Exporting: No
Primary Industry (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Services
Number of Employees: 26
Products:
Nimotuzumab, Aerolef®, Cyt387, Cyt997
Technology:
Clinical Products
The company`s focus on oncology is directed towards both active
and passive immunotherapy, as well as traditional small
molecules. All of YMB`s clinical products have issued
and pending patents protecting the IP.
Allan David
Richard Barb
No associations
LandOfFree
YM BioSciences Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with YM BioSciences Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and YM BioSciences Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-40998